P/E ratio for Minerva Neurosciences (NERV)
P/E ratio as of May 2024 (TTM): -0.4719
According to Minerva Neurosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.471888. At the end of 2022 the company had a P/E ratio of -0.2646.
P/E ratio history for Minerva Neurosciences from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.2646 | -61.32% |
| 2021 | -0.6839 | -102.05% |
| 2020 | 33.4 | -974.5% |
| 2019 | -3.82 | -26.84% |
| 2018 | -5.22 | -27.46% |
| 2017 | -7.20 | -39.32% |
| 2016 | -11.9 | 128.77% |
| 2015 | -5.19 | 127.54% |
| 2014 | -2.28 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Incyte INCY | 27.9 | -6,021.34% | 🇺🇸 USA |
 Dynavax Technologies
DVAX | 13.5 | -2,954.77% | 🇺🇸 USA |
 Clovis Oncology CLVS | -0.0430 | -90.90% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.